{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:46:55Z","timestamp":1767988015659,"version":"3.49.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003593","name":"conselho nacional de desenvolvimento cient\u00edfico e tecnol\u00f3gico","doi-asserted-by":"publisher","award":["310071\/2018-6"],"award-info":[{"award-number":["310071\/2018-6"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005668","name":"funda\u00e7\u00e3o de apoio \u00e0 pesquisa do distrito federal","doi-asserted-by":"publisher","award":["0193.001642\/2017"],"award-info":[{"award-number":["0193.001642\/2017"]}],"id":[{"id":"10.13039\/501100005668","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Model"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00894-021-04925-8","type":"journal-article","created":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T20:16:20Z","timestamp":1633119380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Investigation on the interaction behavior of afatinib, dasatinib, and imatinib docked to the BCR-ABL protein"],"prefix":"10.1007","volume":"27","author":[{"given":"Kelvyn M. L.","family":"Rocha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9rica C. M.","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o B. L.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,1]]},"reference":[{"key":"4925_CR1","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/J.CCELL.2020.03.006","volume":"37","author":"TP Braun","year":"2020","unstructured":"Braun TP, Eide CA, Druker BJ (2020) Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell 37:530\u2013542. https:\/\/doi.org\/10.1016\/J.CCELL.2020.03.006","journal-title":"Cancer Cell"},{"key":"4925_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/J.TRANSCI.2014.10.016","volume":"51","author":"YM Mosaad","year":"2014","unstructured":"Mosaad YM (2014) Hematopoietic stem cells: an overview. Transfus Apher Sci 51:68\u201382. https:\/\/doi.org\/10.1016\/J.TRANSCI.2014.10.016","journal-title":"Transfus Apher Sci"},{"issue":"17","key":"4925_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12943-018-0780-6","volume":"171","author":"S Soverini","year":"2018","unstructured":"Soverini S, Mancini M, Bavaro L et al (2018) (2018) Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer 171(17):1\u201315. https:\/\/doi.org\/10.1186\/S12943-018-0780-6","journal-title":"Mol Cancer"},{"key":"4925_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/J.GTC.2018.04.009","volume":"47","author":"BP Sjoberg","year":"2018","unstructured":"Sjoberg BP, Menias CO, Lubner MG et al (2018) Splenomegaly: a combined clinical and radiologic approach to the differential diagnosis. Gastroenterol Clin North Am 47:643\u2013666. https:\/\/doi.org\/10.1016\/J.GTC.2018.04.009","journal-title":"Gastroenterol Clin North Am"},{"key":"4925_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/J.BEHA.2016.10.005","volume":"29","author":"R Hehlmann","year":"2016","unstructured":"Hehlmann R, Sau\u00dfele S, Voskanyana A, Silver RT (2016) Management of CML-blast crisis. Best Pract Res Clin Haematol 29:295\u2013307. https:\/\/doi.org\/10.1016\/J.BEHA.2016.10.005","journal-title":"Best Pract Res Clin Haematol"},{"key":"4925_CR6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/J.LEUKRES.2004.07.008","volume":"29","author":"LAF Pelloso","year":"2005","unstructured":"Pelloso LAF, Vaz De Campos MG, Nascimento M et al (2005) Chronic myeloid leukemia following kidney transplantation. Leuk Res 29:353\u2013355. https:\/\/doi.org\/10.1016\/J.LEUKRES.2004.07.008","journal-title":"Leuk Res"},{"key":"4925_CR7","doi-asserted-by":"publisher","unstructured":"Soverini S, Bassan R, Lion T (2019) Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. J Hematol Oncol 12:. https:\/\/doi.org\/10.1186\/S13045-019-0729-2","DOI":"10.1186\/S13045-019-0729-2"},{"key":"4925_CR8","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1038\/onc.2011.156","volume":"30","author":"SJ Stein","year":"2011","unstructured":"Stein SJ, Baldwin AS (2011) NF-B suppresses ROS levels in BCR-ABL+ cells to prevent activation of JNK and cell death. Oncogene 30:4557\u20134566. https:\/\/doi.org\/10.1038\/onc.2011.156","journal-title":"Oncogene"},{"key":"4925_CR9","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1182\/BLOOD-2010-12-322537","volume":"118","author":"Z Sheng","year":"2011","unstructured":"Sheng Z, Ma L, Sun JE et al (2011) BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription. Blood 118:2840\u20132848. https:\/\/doi.org\/10.1182\/BLOOD-2010-12-322537","journal-title":"Blood"},{"key":"4925_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1182\/ASHEDUCATION-2018.1.161","volume":"2018","author":"S Claudiani","year":"2018","unstructured":"Claudiani S, Apperley JF (2018) The argument for using imatinib in CML. Hematol Am Soc Hematol Educ Progr 2018:161\u2013167. https:\/\/doi.org\/10.1182\/ASHEDUCATION-2018.1.161","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"4925_CR11","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1182\/BLOOD-2006-05-025049","volume":"109","author":"FJ Giles","year":"2007","unstructured":"Giles FJ, Cortes J, Jones D et al (2007) MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109:500\u2013502. https:\/\/doi.org\/10.1182\/BLOOD-2006-05-025049","journal-title":"Blood"},{"issue":"31","key":"4925_CR12","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/leu.2016.353","volume":"315","author":"BJ Lee","year":"2017","unstructured":"Lee BJ (2017) Shah NP (2016) Identification and characterization of activating ABL1 1b kinase mutations: impact on sensitivity to ATP-competitive and allosteric ABL1 inhibitors. Leuk 315(31):1096\u20131107. https:\/\/doi.org\/10.1038\/leu.2016.353","journal-title":"Leuk"},{"key":"4925_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejca.2018.11.030","volume":"109","author":"WV Lai","year":"2019","unstructured":"Lai WV, Lebas L, Barnes TA et al (2019) Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. Eur J Cancer 109:28\u201335. https:\/\/doi.org\/10.1016\/j.ejca.2018.11.030","journal-title":"Eur J Cancer"},{"key":"4925_CR14","doi-asserted-by":"publisher","unstructured":"Muresan B, Mamolo C, Cappelleri JC, et al (2021) An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia. 37:801\u2013809. https:\/\/doi.org\/10.1080\/03007995.2021.1896489","DOI":"10.1080\/03007995.2021.1896489"},{"key":"4925_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1021\/bk-1999-0719.ch001","volume":"719","author":"MR Reddy","year":"1999","unstructured":"Reddy MR, Parrill AL (1999) Overview of rational drug design. ACS Symp Ser 719:1\u201311. https:\/\/doi.org\/10.1021\/bk-1999-0719.ch001","journal-title":"ACS Symp Ser"},{"key":"4925_CR16","doi-asserted-by":"crossref","unstructured":"Lindauer M, Hochhaus A (2018) Dasatinib. In: Recent results in cancer research. Recent Results Cancer Res, pp 29\u201368","DOI":"10.1007\/978-3-319-91439-8_2"},{"key":"4925_CR17","doi-asserted-by":"publisher","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","volume":"114","author":"MC M\u00fcller","year":"2009","unstructured":"M\u00fcller MC, Cortes JE, Kim D-W et al (2009) Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 114:4944\u20134953. https:\/\/doi.org\/10.1182\/blood-2009-04-214221","journal-title":"Blood"},{"key":"4925_CR18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S1470-2045(07)70078-5","volume":"8","author":"S Soverini","year":"2007","unstructured":"Soverini S, Martinelli G, Colarossi S et al (2007) Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL. Lancet Oncol 8:273\u2013274. https:\/\/doi.org\/10.1016\/S1470-2045(07)70078-5","journal-title":"Lancet Oncol"},{"key":"4925_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/S40262-016-0440-1","volume":"56","author":"S Wind","year":"2017","unstructured":"Wind S, Schnell D, Ebner T et al (2017) Clinical pharmacokinetics and pharmacodynamics of afatinib. Clin Pharmacokinet 56:235\u2013250. https:\/\/doi.org\/10.1007\/S40262-016-0440-1","journal-title":"Clin Pharmacokinet"},{"key":"4925_CR20","doi-asserted-by":"publisher","unstructured":"Jr RR (2014) The ErbB\/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 79:34\u201374. https:\/\/doi.org\/10.1016\/J.PHRS.2013.11.002","DOI":"10.1016\/J.PHRS.2013.11.002"},{"key":"4925_CR21","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.lungcan.2012.05.110","volume":"77","author":"M Scheffler","year":"2012","unstructured":"Scheffler M, Kobe C, Zander T et al (2012) Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PET. Lung Cancer 77:617\u2013620. https:\/\/doi.org\/10.1016\/j.lungcan.2012.05.110","journal-title":"Lung Cancer"},{"key":"4925_CR22","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s40265-013-0111-6","volume":"73","author":"RT Dungo","year":"2013","unstructured":"Dungo RT, Keating GM (2013) Afatinib: first global approval. Drugs 73:1503\u20131515. https:\/\/doi.org\/10.1007\/s40265-013-0111-6","journal-title":"Drugs"},{"key":"4925_CR23","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1517\/13543784.2014.924505","volume":"23","author":"SA Hurvitz","year":"2014","unstructured":"Hurvitz SA, Shatsky R, Harbeck N (2014) Afatinib in the treatment of breast cancer. Expert Opin Investig Drugs 23:1039\u20131047. https:\/\/doi.org\/10.1517\/13543784.2014.924505","journal-title":"Expert Opin Investig Drugs"},{"key":"4925_CR24","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40265-013-0170-8","volume":"74","author":"GM Keating","year":"2014","unstructured":"Keating GM (2014) Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer. Drugs 74:207\u2013221. https:\/\/doi.org\/10.1007\/s40265-013-0170-8","journal-title":"Drugs"},{"key":"4925_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/4201727","volume":"2020","author":"K Watanabe","year":"2020","unstructured":"Watanabe K, Kage H, Nagoshi S et al (2020) Dual EGFR and ABL tyrosine kinase inhibitor treatment in a patient with concomitant EGFR-mutated lung adenocarcinoma and BCR-ABL1-positive CML. Case Rep Oncol Med 2020:1\u20136. https:\/\/doi.org\/10.1155\/2020\/4201727","journal-title":"Case Rep Oncol Med"},{"key":"4925_CR26","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0092-8674(03)00194-6","volume":"112","author":"B Nagar","year":"2003","unstructured":"Nagar B, Hantschel O, Young MA et al (2003) Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112:859\u2013871. https:\/\/doi.org\/10.1016\/S0092-8674(03)00194-6","journal-title":"Cell"},{"key":"4925_CR27","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0300-9084(87)90029-0","volume":"69","author":"J-J Feige","year":"1987","unstructured":"Feige J-J, Chambaz EM (1987) Membrane receptors with protein-tyrosine kinase activity. Biochimie 69:379\u2013385. https:\/\/doi.org\/10.1016\/0300-9084(87)90029-0","journal-title":"Biochimie"},{"key":"4925_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1107\/S0907444909042073","volume":"66","author":"VB Chen","year":"2010","unstructured":"Chen VB, Arendall WB, Headd JJ et al (2010) MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr Sect D Biol Crystallogr 66:12\u201321. https:\/\/doi.org\/10.1107\/S0907444909042073","journal-title":"Acta Crystallogr Sect D Biol Crystallogr"},{"key":"4925_CR29","doi-asserted-by":"publisher","first-page":"10089","DOI":"10.1021\/J100091A024","volume":"98","author":"K Kim","year":"2002","unstructured":"Kim K, Jordan KD (2002) Comparison of density functional and MP2 calculations on the water monomer and dimer. J Phys Chem 98:10089\u201310094. https:\/\/doi.org\/10.1021\/J100091A024","journal-title":"J Phys Chem"},{"key":"4925_CR30","unstructured":"Frisch MJ, Trucksr GW, Schlegel HB, et al (2009) Gaussian 09, Revision D.01. Gaussian"},{"issue":"1","key":"4925_CR31","first-page":"2","volume":"4","author":"R Dennington","year":"2007","unstructured":"Dennington R, Keith T, Millam J (2007) Gauss view. Version 4(1):2","journal-title":"Version"},{"key":"4925_CR32","unstructured":"Zhurko GA (2005) Chemcraft - graphical software for visualization of quantum chemistry"},{"key":"4925_CR33","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris GM, Huey R, Lindstrom W et al (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30:2785\u20132791. https:\/\/doi.org\/10.1002\/jcc.21256","journal-title":"J Comput Chem"},{"key":"4925_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/0263-7855(96)00018-5","author":"W Humphrey","year":"1996","unstructured":"Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph. https:\/\/doi.org\/10.1016\/0263-7855(96)00018-5","journal-title":"J Mol Graph"},{"key":"4925_CR35","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1139\/V06-012","volume":"84","author":"EA Wiley","year":"2006","unstructured":"Wiley EA, MacDonald M, Lambropoulos A et al (2006) LGA-dock\/EM-dock exploring Lamarckian genetic algorithms and energy-based local search for ligand receptor docking. Can J Chem 84:384\u2013391. https:\/\/doi.org\/10.1139\/V06-012","journal-title":"Can J Chem"},{"key":"4925_CR36","unstructured":"Syst\u00e8mes D (2015) Discovery studio. BIOVIA"},{"key":"4925_CR37","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/jcc.22885","volume":"33","author":"T Lu","year":"2012","unstructured":"Lu T, Chen F (2012) Multiwfn: a multifunctional wavefunction analyzer. J Comput Chem 33:580\u2013592. https:\/\/doi.org\/10.1002\/jcc.22885","journal-title":"J Comput Chem"},{"issue":"39","key":"4925_CR38","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41388-019-1001-5","volume":"393","author":"N Kiavue","year":"2019","unstructured":"Kiavue N, Cabel L, Melaabi S et al (2019) (2019) ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics. Oncogene 393(39):487\u2013502. https:\/\/doi.org\/10.1038\/s41388-019-1001-5","journal-title":"Oncogene"},{"issue":"28","key":"4925_CR39","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/S00044-019-02437-Y","volume":"2811","author":"SE Fioressi","year":"2019","unstructured":"Fioressi SE, Bacelo DE (2019) Duchowicz PR (2019) QSAR study of human epidermal growth factor receptor (EGFR) inhibitors: conformation-independent models. Med Chem Res 2811(28):2079\u20132087. https:\/\/doi.org\/10.1007\/S00044-019-02437-Y","journal-title":"Med Chem Res"},{"key":"4925_CR40","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","volume":"66","author":"JS Tokarski","year":"2006","unstructured":"Tokarski JS, Newitt JA, Chang CYJ et al (2006) The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 66:5790\u20135797. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-4187","journal-title":"Cancer Res"},{"key":"4925_CR41","doi-asserted-by":"publisher","unstructured":"Pereira WA, Nascimento \u00c9CM, Martins JBL (2021) Electronic and structural study of T315I mutated form in DFG-out conformation of BCR-ABL inhibitors. 101080\/0739110220211935320. https:\/\/doi.org\/10.1080\/07391102.2021.1935320","DOI":"10.1080\/07391102.2021.1935320"},{"key":"4925_CR42","doi-asserted-by":"publisher","unstructured":"Martins P, Jesus J, Santos S, et al (2015) Heterocyclic anticancer compounds: recent advances and the paradigm shift towards the use of nanomedicine\u2019s tool box. Mol 2015, Vol 20, Pages 16852\u201316891 20:16852\u201316891. https:\/\/doi.org\/10.3390\/MOLECULES200916852","DOI":"10.3390\/MOLECULES200916852"},{"key":"4925_CR43","doi-asserted-by":"publisher","first-page":"8227","DOI":"10.1021\/JA311756U","volume":"135","author":"H Park","year":"2013","unstructured":"Park H, Hong S, Kim J, Hong S (2013) Discovery of picomolar ABL kinase inhibitors equipotent for wild type and T315I mutant via structure-based de novo design. J Am Chem Soc 135:8227\u20138237. https:\/\/doi.org\/10.1021\/JA311756U","journal-title":"J Am Chem Soc"},{"key":"4925_CR44","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/07391102.2001.10506725","volume":"19","author":"D Pal","year":"2001","unstructured":"Pal D, Chakrabarti P (2001) Non-hydrogen bond interactions involving the methionine sulfur atom. J Biomol Struct Dyn 19:115\u2013128. https:\/\/doi.org\/10.1080\/07391102.2001.10506725","journal-title":"J Biomol Struct Dyn"},{"key":"4925_CR45","doi-asserted-by":"crossref","unstructured":"Wishart DS Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z, Woolsey J. KC (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration. In: Nucleic Acids Res.","DOI":"10.1093\/nar\/gkj067"},{"issue":"100","key":"4925_CR46","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/S00277-021-04477-0","volume":"1005","author":"E Scalzulli","year":"2021","unstructured":"Scalzulli E, Caocci G, Efficace F et al (2021) Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients. Ann Hematol 1005(100):1213\u20131219. https:\/\/doi.org\/10.1007\/S00277-021-04477-0","journal-title":"Ann Hematol"},{"key":"4925_CR47","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00228-015-1968-y","volume":"72","author":"Y Ishida","year":"2016","unstructured":"Ishida Y, Murai K, Yamaguchi K et al (2016) Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia. Eur J Clin Pharmacol 72:185\u2013193. https:\/\/doi.org\/10.1007\/s00228-015-1968-y","journal-title":"Eur J Clin Pharmacol"},{"key":"4925_CR48","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.1182\/BLOOD.V118.21.4444.4444","volume":"118","author":"T Akagi","year":"2011","unstructured":"Akagi T, Murai K, Shimosegawa K et al (2011) Efficacy and safety of dasatinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance. Blood 118:4444. https:\/\/doi.org\/10.1182\/BLOOD.V118.21.4444.4444","journal-title":"Blood"},{"key":"4925_CR49","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1080\/10428194.2018.1443330","volume":"59","author":"RL Redner","year":"2018","unstructured":"Redner RL, Beumer JH, Kropf P et al (2018) A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia. Leuk Lymphoma 59:2595\u20132601. https:\/\/doi.org\/10.1080\/10428194.2018.1443330","journal-title":"Leuk Lymphoma"},{"key":"4925_CR50","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2165\/11535870-000000000-00000","volume":"24","author":"F Condorelli","year":"2010","unstructured":"Condorelli F, Genazzani AA (2010) Dasatinib BioDrugs 24:157\u2013163. https:\/\/doi.org\/10.2165\/11535870-000000000-00000","journal-title":"Dasatinib BioDrugs"},{"key":"4925_CR51","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1182\/BLOOD.V104.11.1982.1982","volume":"104","author":"J Miljus","year":"2004","unstructured":"Miljus J, Melo JV, Boros L et al (2004) Metabolic profile of imatinib resistance in CML cells. Blood 104:1982. https:\/\/doi.org\/10.1182\/BLOOD.V104.11.1982.1982","journal-title":"Blood"}],"container-title":["Journal of Molecular Modeling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00894-021-04925-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00894-021-04925-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00894-021-04925-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T21:56:34Z","timestamp":1634075794000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00894-021-04925-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["4925"],"URL":"https:\/\/doi.org\/10.1007\/s00894-021-04925-8","relation":{},"ISSN":["1610-2940","0948-5023"],"issn-type":[{"value":"1610-2940","type":"print"},{"value":"0948-5023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"21 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"309"}}